Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Novel therapies for children with severe asthma
Top Ten Searches
hla beta 2 probiotics hypo allergenic scid urticaria aeroallergens asthma angioedema hivYour Article Summary
Update on Inflammation, Neurodegeneration, and Immunoregulation in Multiple Sclerosis: Therapeutic Implications
Clinical Neuropharmacology, 06/01/09
Bennett JL et al. - Although CD4+ T lymphocytes have long been implicated in the immunopathology of MS, the role of other T-cell subtypes has been recognized. CD4+ and CD8+ cells have been isolated from different locations within MS lesions and gamma/delta T cells have been isolated from early MS lesions. The prevalent dogma has been that CD4+ TH1 cells release cytokines and mediators of inflammation that may cause tissue damage, although CD4+ TH2 cells may be involved in modulation of these effects. Recent evidence, however, suggests that additional T-cell subsets play a prominent role in MS immunopathology: TH17 cells, CD8+ effector T cells, and CD4+CD25+ regulatory T cells. In addition, laboratory and clinical data are accumulating on the prominent role of B lymphocytes and antigen-presenting cells in MS pathogenesis. On the basis of these observations, new therapeutic approaches for MS will need to focus on resetting multiple components of the immune system.
Related Articles
APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis
Multiple Sclerosis, 11/19/09
Relevance Score: 69%
Early Psychiatric Manifestation in a Patient with Primary Progressive Multiple Sclerosis
Archives of Iranian Medicine, 11/12/09
Relevance Score: 69%
Cochlear implantation in a profoundly deaf patient who also suffers from multiple sclerosis - a case study
Cochlear Implants International, 10/27/09
Relevance Score: 69%
A single-centre, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
Multiple Sclerosis, 10/01/09
Relevance Score: 69%
Early Drug Treatment May Cut Multiple Sclerosis Risk
MedLinePlus, 10/08/09
Relevance Score: 68%
Today in Neurologic/Ophthalmic...keeping you current
Receive free subspecialty "5-minute updates" via email
Beta-Defensins 2 and 3 Together Promote Resistance to Pseudomonas aeruginosa Keratitis
Journal of Immunology, 12/10/09
Divergent effects of norepinephrine, dopamine and substance P on the activation, differentiation and effector functions of human cytotoxic T lymphocytes
BMC Immunology, 12/09/09
Evidence of STAT5-dependent and -independent routes to CD8 memory formation and a preferential role for IL-7 over IL-15 in STAT5 activation
Immunology & Cell Biology, 12/08/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


